Mark B. Pepys

35.4k total citations · 8 hit papers
251 papers, 26.2k citations indexed

About

Mark B. Pepys is a scholar working on Molecular Biology, Physiology and Surgery. According to data from OpenAlex, Mark B. Pepys has authored 251 papers receiving a total of 26.2k indexed citations (citations by other indexed papers that have themselves been cited), including 130 papers in Molecular Biology, 58 papers in Physiology and 51 papers in Surgery. Recurrent topics in Mark B. Pepys's work include Amyloidosis: Diagnosis, Treatment, Outcomes (103 papers), Alzheimer's disease research and treatments (45 papers) and Pancreatitis Pathology and Treatment (32 papers). Mark B. Pepys is often cited by papers focused on Amyloidosis: Diagnosis, Treatment, Outcomes (103 papers), Alzheimer's disease research and treatments (45 papers) and Pancreatitis Pathology and Treatment (32 papers). Mark B. Pepys collaborates with scholars based in United Kingdom, United States and Italy. Mark B. Pepys's co-authors include Philip N. Hawkins, M L Baltz, J. Ruth Gallimore, Margaret Sunde, Paul E. Fraser, Glenys A. Tennent, Colin Blake, Julian D. Gillmore, Louise C. Serpell and Giovanna Liuzzo and has published in prestigious journals such as Nature, New England Journal of Medicine and Proceedings of the National Academy of Sciences.

In The Last Decade

Mark B. Pepys

248 papers receiving 25.1k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The Prognostic Value of C-Reactive Protein and Serum Amyloid A Protein in Severe Unstable Angina

1994 1.9k citations J. Ruth Gallimore, Mark B. Pepys et al. profile →
Common core structure of amyloid fibrils by synchrotron X-ray diffraction 1 1Edited by F. E. Cohen

1997 1.4k citations Margaret Sunde, Paul E. Fraser et al. profile →
Acute Phase Proteins with Special Reference to C-Reactive Protein and Related Proteins (Pentaxins) and Serum Amyloid A Protein

1983 1.1k citations Mark B. Pepys, M L Baltz Advances in immunology profile →
Instability, unfolding and aggregation of human lysozyme variants underlying amyloid fibrillogenesis

1997 891 citations David R. Booth, Margaret Sunde et al. Nature profile →
The physiological structure of human C-reactive protein and its complex with phosphocholine

1999 621 citations Mark B. Pepys et al. profile →
Human lysozyme gene mutations cause hereditary systemic amyloidosis

1993 550 citations Mark B. Pepys, Philip N. Hawkins et al. Nature profile →
C-REACTIVE PROTEIN FIFTY YEARS ON

1981 546 citations Mark B. Pepys profile →
Metabolic and scintigraphic studies of radioiodinated human C-reactive protein in health and disease.

1993 489 citations Mark B. Pepys, Philip N. Hawkins et al. Journal of Clinical Investigation profile →

Peers

Countries citing papers authored by Mark B. Pepys

Since Specialization

Citations

This map shows the geographic impact of Mark B. Pepys's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark B. Pepys with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark B. Pepys more than expected).

Fields of papers citing papers by Mark B. Pepys

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark B. Pepys. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark B. Pepys. The network helps show where Mark B. Pepys may publish in the future.

Co-authorship network of co-authors of Mark B. Pepys

This figure shows the co-authorship network connecting the top 25 collaborators of Mark B. Pepys. A scholar is included among the top collaborators of Mark B. Pepys based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark B. Pepys. Mark B. Pepys is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Genetic evidence for serum amyloid P component as a drug target in neurodegenerative disorders 2024 ·Open Biology ·Amand F. Schmidt, Chris Finan, Sandesh Chopade, Stéphan Ellmerich, Martin N. Rossor, Aroon D. Hingorani, Mark B. Pepys	4
2	Serum amyloid P component accumulates and persists in neurones following traumatic brain injury 2023 ·Open Biology ·Ping K. Yip, Zhuo‐Hao Liu, (unknown), Mark B. Pepys, Christopher Uff	4
3	Plasmin activity promotes amyloid deposition in a transgenic model of human transthyretin amyloidosis 2021 ·Nature Communications ·(unknown), (unknown), Stéphan Ellmerich, (unknown), Janet A. Gilbertson, (unknown), Diana Canetti, Graham W. Taylor, Nigel B. Rendell, Glenys A. Tennent, Guglielmo Verona, Riccardo Porcari, P. Patrizia Mangione, Julian D. Gillmore, Mark B. Pepys, (unknown), Philip N. Hawkins, Raya Al‐Shawi, J. Paul Simons	18
4	Inhibition of the mechano-enzymatic amyloidogenesis of transthyretin: role of ligand affinity, binding cooperativity and occupancy of the inner channel 2017 ·Scientific Reports ·Guglielmo Verona, P. Patrizia Mangione, Sara Raimondi, Sofia Giorgetti, (unknown), Riccardo Porcari, Alessandra Corazza, Julian D. Gillmore, Philip N. Hawkins, Mark B. Pepys, Graham W. Taylor, Vittorio Bellotti	34
5	Lack of effect of a single injection of human C‐reactive protein on murine lupus or nephrotoxic nephritis 2009 ·Arthritis & Rheumatism ·Francesco Carlucci, H. Terence Cook, (unknown), Mark B. Pepys, Marina Botto	17
6	Human Serum Amyloid P Component Protects againstEscherichia coliO157:H7 Shiga Toxin 2 In Vivo: Therapeutic Implications for Hemolytic‐Uremic Syndrome 2006 ·The Journal of Infectious Diseases ·Glen D. Armstrong, George L. Mulvey, Paola Marcato, Thomas P. Griener, Melvyn Kahan, Glenys A. Tennent, Caroline Sabin, Henrik Chart, Mark B. Pepys	41
7	Inflammation and Endothelial Function 2005 ·Circulation ·Brian Clapp, Gideon M. Hirschfield, Clare Storry, J. Ruth Gallimore, Ray Stidwill, Mervyn Singer, John Deanfield, Raymond J. MacAllister, Mark B. Pepys, Patrick Vallance, Aroon D. Hingorani	145
8	Human C-Reactive Protein Does Not Protect against Acute Lipopolysaccharide Challenge in Mice 2003 ·The Journal of Immunology ·Gideon M. Hirschfield, Jeff Herbert, Melvyn Kahan, Mark B. Pepys	31
9	Hereditary renal amyloidosis associated with variant lysozyme in a large English family 1999 ·Nephrology Dialysis Transplantation ·Julian D. Gillmore, David R. Booth, S. Madhoo, Mark B. Pepys, Philip N. Hawkins	57
10	The liver in systemic amyloidosis: insights from ¹²³ I serum amyloid P component scintigraphy in 484 patients 1998 ·Gut ·Laurence Lovat, M.R. Persey, S. Madhoo, Mark B. Pepys, Philip N. Hawkins	83
11	Instability, unfolding and aggregation of human lysozyme variants underlying amyloid fibrillogenesis breakdown → 1997 ·Nature ·David R. Booth, Margaret Sunde, Vittorio Bellotti, Carol V. Robinson, Winston L. Hutchinson, Paul E. Fraser, Philip N. Hawkins, Christopher M. Dobson, Sheena E. Radford, Colin Blake, Mark B. Pepys	891
12	Hereditary hepatic and systemic amyloidosis caused by a new deletion/insertion mutation in the apolipoprotein AI gene. 1996 ·Journal of Clinical Investigation ·David R. Booth, Shouyong Tan, S E Booth, GA Tennent, W. L. Hutchinson, J. Justin Hsuan, Nicholas F. Totty, O Truong, Anne K. Soutar, Philip N. Hawkins, Miquel Bruguera, Joan Caballería, (unknown), Josep M. Campistol, Mark B. Pepys	75
13	Isolation and characterization of the integral glycosaminoglycan constituents of human amyloid A and monoclonal light-chain amyloid fibrils 1991 ·Biochemical Journal ·Stephen Nelson, Malcolm Lyon, J. T. Gallagher, Edward A. Johnson, Mark B. Pepys	60
14	Differing acute phase responses in Crohn's disease and ulcerative colitis. 1986 ·Gut ·S.H. Saverymuttu, H J Hodgson, V. S. Chadwick, Mark B. Pepys	108
15	C‐reactive protein in patients undergoing cardiac surgery 1986 ·Anaesthesia ·H. Boralessa, Frederick C. de Beer, (unknown), J.G. WHITWAM, Mark B. Pepys	43
16	Objective monitoring of disease activity in polyarteritis by measurement of serum C reactive protein concentration. 1984 ·BMJ ·C R Hind, Caroline O. S. Savage, Christopher G. Winearls, Mark B. Pepys	23
17	Rabbit and rat C-reactive proteins bind apolipoprotein B-containing lipoproteins. 1984 ·The Journal of Experimental Medicine ·Ian Rowe, A.K. Soutar, I. Trayner, M L Baltz, Frederick C. de Beer, Lucy S. K. Walker, David E. Bowyer, J. Herbert, A. Feinstein, Mark B. Pepys	38
18	Acute Phase Proteins with Special Reference to C-Reactive Protein and Related Proteins (Pentaxins) and Serum Amyloid A Protein breakdown → 1983 ·Advances in immunology ·Mark B. Pepys, M L Baltz	1054
19	The acute-phase response in (NZB X NZW)F1 and MRL/l MICE. 1982 ·The Journal of Experimental Medicine ·Christiane Rordorf, (unknown), M L Baltz, Glenys A. Tennent, Mark B. Pepys	36
20	Amyloid P-component is a constituent of normal human glomerular basement membrane. 1980 ·The Journal of Experimental Medicine ·Roland Dyck, C M Lockwood, Michael J. Kershaw, Neil McHugh, Victor C. Duance, M L Baltz, Mark B. Pepys	179

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact